KalVista (NASDAQ: KALV) sets 2026 meeting and proxy deadlines

Rhea-AI Filing Summary

KalVista Pharmaceuticals, Inc. has set June 18, 2026 as the date of its 2026 Annual Meeting of Stockholders. The specific time and location will be provided in the company’s definitive proxy statement to be filed before the meeting.

Because this meeting date differs by more than 30 days from the prior year’s annual meeting, stockholder proposals seeking inclusion in the 2026 proxy materials must be submitted in writing to the Corporate Secretary by January 6, 2026. Under the company’s Amended and Restated Bylaws, stockholders wishing to present other proposals at the meeting or nominate directors must deliver notice by August 31, 2025, and must also comply with the universal proxy requirements of Rule 14a-19 for any competing director nominations.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

false 0001348911 0001348911 2025-08-21 2025-08-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 21, 2025

KALVISTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-36830		20-0915291
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

55 Cambridge Parkway Suite 901E
Cambridge, Massachusetts		02142
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 999-0075

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		KALV		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

KalVista Pharmaceuticals, Inc. (the “Company”) has set June 18, 2026 as the date of the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). The time and location of the Annual Meeting will be set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting to be filed with the Securities and Exchange Commission prior to the 2026 Annual Meeting.

Since the date of the 2026 Annual Meeting has changed by more than 30 days from the date of the Company’s 2025 Annual Meeting of Stockholders, in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), stockholder proposals to be considered for inclusion in the proxy materials for the 2026 Annual Meeting must be submitted in writing by January 6, 2026, to the Company’s Corporate Secretary at 55 Cambridge Parkway, Suite 901E, Cambridge, Massachusetts 02142, which the Company believes is a reasonable time before it begins to print and send its proxy materials for the 2026 Annual Meeting.

Pursuant to the Company’s Amended and Restated Bylaws (the “Bylaws”), in order for a stockholder to present a proposal for the 2026 Annual Meeting, other than proposals to be included in the proxy statement as described above, or to nominate a director, stockholders must give notice on or before August 31, 2025, the 10th day after the date of this Current Report on Form 8-K announcing the date of the 2026 Annual Meeting. Stockholders are also advised to review the Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations.

In addition to complying with the procedures of the Bylaws, including the notice deadlines set forth above and therein, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees, other than the Company’s nominees, must also comply with the additional requirements of Rule 14a-19 under the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						KALVISTA PHARMACEUTICALS, INC.
Date: August 21, 2025				By:		/s/ Brian Piekos
						Brian Piekos
						Chief Financial Officer (Principal Financial and Accounting Officer)

FAQ

When is KalVista (KALV) holding its 2026 Annual Meeting of Stockholders?

KalVista Pharmaceuticals, Inc. has set its 2026 Annual Meeting of Stockholders for June 18, 2026. The time and location will be specified in the company’s definitive proxy statement filed before the meeting.

What is the deadline for KalVista (KALV) stockholder proposals to be included in the 2026 proxy materials?

To be considered for inclusion in the proxy materials for the 2026 Annual Meeting, stockholder proposals must be submitted in writing by January 6, 2026 to the Corporate Secretary at 55 Cambridge Parkway, Suite 901E, Cambridge, Massachusetts 02142.

What is the deadline to submit other stockholder proposals or director nominations for KalVistas 2026 meeting?

Under KalVistas Amended and Restated Bylaws, stockholders must give notice of other proposals or director nominations for the 2026 Annual Meeting by August 31, 2025, which is the 10th day after the public announcement of the meeting date.

Where must KalVista (KALV) stockholder proposals for the 2026 Annual Meeting be sent?

Proposals for inclusion in the 2026 proxy materials must be sent in writing to the Companys Corporate Secretary at 55 Cambridge Parkway, Suite 901E, Cambridge, Massachusetts 02142.

What additional rules apply to KalVista stockholders nominating directors for the 2026 meeting?

Stockholders who intend to solicit proxies in support of director nominees other than KalVistas nominees must comply with the companys Bylaws and the universal proxy requirements of Rule 14a-19 under the Exchange Act, in addition to meeting the advance notice deadlines.

Why did KalVista (KALV) disclose new deadlines for 2026 stockholder proposals?

The 2026 Annual Meeting date differs by more than 30 days from the date of the 2025 Annual Meeting, so KalVista set and disclosed new deadlines for stockholder proposals and director nominations in line with Rule 14a-8 and its Bylaws.